- Record: found
- Abstract: not found
- Article: not found
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study
Arjun V Balar ,
Daniel Castellano ,
Peter H O'Donnell ,
Petros Grivas ,
Jacqueline Vuky ,
Thomas Powles ,
Elizabeth R Plimack ,
Noah M Hahn ,
Ronald de Wit ,
Lei Pang ,
Mary J Savage ,
Rodolfo F Perini ,
Stephen M Keefe ,
Dean Bajorin ,
Joaquim Bellmunt
November 2017
November 2017
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
<p class="first" id="d2703519e258">More than half of all patients with advanced urothelial
cancer cannot receive standard,
first-line cisplatin-based chemotherapy because of renal dysfunction, poor performance
status, or other comorbidities. We assessed the activity and safety of first-line
pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable
or metastatic urothelial cancer.
</p>